Skip to main content

Advertisement

SpringerLink
Log in

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Concurrent use of tamoxifen and cytochrome P450 2D6 (CYP2D6) inhibitors, such as selective serotonin reuptake inhibitors, has been shown to decrease plasma concentrations of tamoxifen metabolites. However, it is still unclear whether such concurrent use affects tamoxifen’s effectiveness. Thus, the objective of this study is to determine whether concurrent use of tamoxifen with CYP2D6 inhibitors increases the risk of recurrence in patients newly diagnosed with breast cancer. We conducted a nested case–control analysis within a population-based cohort from the UK General Practice Research Database. The cohort included women with a first-ever diagnosis of breast cancer who were prescribed tamoxifen between January 1, 1998 and June 30, 2008. Cases consisted of all patients with a breast cancer recurrence occurring during follow-up. Up to ten controls were matched to each case on year of birth, date of cohort entry, and duration of follow-up. Conditional logistic regression was used to estimate rate ratios (RR) of breast cancer recurrence in patients who concurrently used tamoxifen with CYP2D6 inhibitors, compared to patients who only used tamoxifen. The cohort included 9,209 incident users of tamoxifen, of whom 807 were diagnosed with a breast cancer recurrence. Concurrent use was not associated with an increased incidence of breast cancer recurrence (adjusted RR 1.07, 95% 0.88, 1.30). Type and strength of CYP2D6 inhibitors, as well as duration of concurrent use did not affect breast cancer recurrence. These results remained consistent after performing sensitivity analyses. The results of this large population-based study indicate that concurrent use of tamoxifen with CYP2D6 inhibitors does not increase the risk of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  2. Perez EA (2007) Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Ann Oncol 18(Suppl 8):viii26–viii35

    Article  PubMed  Google Scholar 

  3. Jordan VC (2007) New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 72:829–842

    Article  PubMed  CAS  Google Scholar 

  4. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13

    Article  PubMed  CAS  Google Scholar 

  5. Seruga B, Amir E (2010) Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis. Breast Cancer Res Treat 122:609–617

    Article  PubMed  CAS  Google Scholar 

  6. Lacy C, Armstrong L, Goldman M, Lance L (2007) Cytochrome P450 enzymes: substrates, inhibitors, and inducers. In: Lacy C, Armstrong L, Goldman M, Lance L (eds) Drug information handbook, 15th edn. LexiComp Inc., Hudson, pp 1899–1912

  7. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764

    PubMed  CAS  Google Scholar 

  8. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30–39

    Article  PubMed  CAS  Google Scholar 

  9. Lehmann D, Nelsen J, Ramanath V, Newman N, Duggan D, Smith A (2004) Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition. J Clin Pharmacol 44:861–865

    Article  PubMed  CAS  Google Scholar 

  10. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113–121

    Article  PubMed  CAS  Google Scholar 

  11. Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL et al (2008) Tamoxifen’s protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 99:616–621

    Article  PubMed  CAS  Google Scholar 

  12. Chubak J, Buist DS, Boudreau DM, Rossing MA, Lumley T, Weiss NS (2008) Breast cancer recurrence risk in relation to antidepressant use after diagnosis. Breast Cancer Res Treat 112:123–132

    Article  PubMed  CAS  Google Scholar 

  13. Ahern TP, Pedersen L, Cronin-Fenton DP, Sorensen HT, Lash TL (2009) No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications. Cancer Epidemiol Biomarkers Prev 18:2562–2564

    Article  PubMed  CAS  Google Scholar 

  14. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA et al (2010) Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 49:305–312

    Article  PubMed  CAS  Google Scholar 

  15. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, Van Herk-Sukel MP, Casparie MK et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423–2429

    Article  PubMed  CAS  Google Scholar 

  16. Siegelmann-Daniel N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M et al. (2010) Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat. doi: 10.1007/s10549-010-1008-7

  17. Holzman D (2009) Tamoxifen, antidepressants, and CYP2D6: the conundrum continues. J Natl Cancer Inst 101:1370–1371

    Article  PubMed  Google Scholar 

  18. Walley T, Mantgani A (1997) The UK General Practice Research Database. Lancet 350:1097–1099

    Article  PubMed  CAS  Google Scholar 

  19. Garcia Rodriguez LA, Perez GS (1998) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45:419–425

    Article  PubMed  CAS  Google Scholar 

  20. Jick H, Jick SS, Derby LE (1991) Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ 302:766–768

    Article  PubMed  CAS  Google Scholar 

  21. Lawrenson R, Williams T, Farmer R (1999) Clinical information for research; the use of general practice databases. J Public Health Med 21:299–304

    Article  PubMed  CAS  Google Scholar 

  22. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD (2000) Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 49:591–596

    Article  PubMed  CAS  Google Scholar 

  23. Jick SS, Kaye JA, Vasilakis-Scaramozza C, Garcia Rodriguez LA, Ruigomez A, Meier CR et al (2003) Validity of the general practice research database. Pharmacotherapy 23:686–689

    Article  PubMed  Google Scholar 

  24. Suissa S (2005) Novel approaches to pharmacoepidemiology study design and statistical analysis. In: Strom B (ed) pharmacoepidemiology, 4th edn. John Wiley & Sons, Chichester England, pp 811–829

    Google Scholar 

  25. Essebag V, Platt RW, Abrahamowicz M, Pilote L (2005) Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 5:5

    Article  PubMed  Google Scholar 

  26. Essebag V, Genest J Jr, Suissa S, Pilote L (2003) The nested case-control study in cardiology. Am Heart J 146:581–590

    Article  PubMed  Google Scholar 

  27. de Vos D, Slee PH, Stevenson D, Briggs RJ (1992) Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer. Cancer Chemother Pharmacol 31:76–78

    Article  PubMed  Google Scholar 

  28. Brewster DH, Thomson CS, Hole DJ, Black RJ, Stroner PL, Gillis CR (2001) Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. BMJ 322:830–831

    Article  PubMed  CAS  Google Scholar 

  29. Carroll DG, Kelley KW (2009) Use of antidepressants for management of hot flashes. Pharmacotherapy 29:1357–1374

    Article  PubMed  CAS  Google Scholar 

  30. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 340:c693

    Article  PubMed  Google Scholar 

  31. Decensi A, Robertson C, Viale G, Pigatto F, Johansson H, Kisanga ER et al (2003) A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 95:779–790

    Article  PubMed  CAS  Google Scholar 

  32. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C et al (2004) Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res 10:2336–2343

    Article  PubMed  CAS  Google Scholar 

  33. Lash TL, Lien EA, Sorensen HT, Hamilton-Dutoit S (2009) Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 10:825–833

    Article  PubMed  CAS  Google Scholar 

  34. Huiart L, Dell’Aniello S, Suissa S (2009) Patterns of use of tamoxifen and aromatase inhibitors: a population-based observational study. J Clin Oncol 27:556

    Google Scholar 

Download references

Acknowledgments

Dr. Laurent Azoulay is the recipient of a ‘Chercheur-Boursier’ Award from the Fonds de la recherche en santé du Québec. Dr. Samy Suissa is the recipient of a Distinguished Investigator Award from the Canadian Institutes of Health Research. This study was supported by the Canadian Institutes of Health Research and Canada Foundation for Innovation.

Conflicts of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Centre for Clinical Epidemiology and Community Studies, Sir Mortimer B. Davis Jewish General Hospital, 3755 Côte Sainte-Catherine, H-425.1, Montreal, QC, H3T 1E2, Canada

    Laurent Azoulay, Sophie Dell’Aniello, Guillaume Galbaud du Fort & Samy Suissa

  2. Department of Oncology, McGill University, Montreal, QC, Canada

    Laurent Azoulay

  3. Département d’oncogénétique, Prévention et Dépistage, Institut Paoli-Calmettes, Marseille, France

    Laetitia Huiart

  4. Inserm, UMR912, SES4, Institut Paoli-Calmettes, Marseille, France

    Laetitia Huiart

  5. Department of Psychiatry, McGill University, Montreal, Canada

    Guillaume Galbaud du Fort

  6. Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

    Samy Suissa

Authors
  1. Laurent Azoulay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sophie Dell’Aniello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laetitia Huiart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guillaume Galbaud du Fort
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samy Suissa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Azoulay.

Appendix

Appendix

See Table 6.

Table 6 Cytochrome P450 CYP2D6 inhibitors and substrates
Full size table

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azoulay, L., Dell’Aniello, S., Huiart, L. et al. Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence. Breast Cancer Res Treat 126, 695–703 (2011). https://doi.org/10.1007/s10549-010-1162-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1162-y

Keywords

Search

Navigation